These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 39039699)

  • 1. Antifibrotic therapy in progressive pulmonary fibrosis: a review of recent advances.
    Naqvi M; Hannah J; Lawrence A; Myall K; West A; Chaudhuri N
    Expert Rev Respir Med; 2024 Jun; 18(6):397-407. PubMed ID: 39039699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the identification and management of progressive pulmonary fibrosis: perspective from Chinese experts.
    Huang H; Wang Q; Xu Z
    Ther Adv Respir Dis; 2024; 18():17534666241288417. PubMed ID: 39415340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
    Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
    Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
    BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive Pulmonary Fibrosis: Where Are We Now?
    Kang HK; Song JW
    Tuberc Respir Dis (Seoul); 2024 Apr; 87(2):123-133. PubMed ID: 38111100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Key learnings from the INBUILD trial in patients with progressive pulmonary fibrosis.
    Mira-Avendano I; Kaye M
    Ther Adv Respir Dis; 2024; 18():17534666241266343. PubMed ID: 39113425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
    Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
    BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interstitial Lung Disease: A Review.
    Maher TM
    JAMA; 2024 May; 331(19):1655-1665. PubMed ID: 38648021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies.
    Wongkarnjana A; Scallan C; Kolb MRJ
    Curr Opin Pulm Med; 2020 Sep; 26(5):436-442. PubMed ID: 32657838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guidelines of the Polish Respiratory Society on the Diagnosis and Treatment of Progressive Fibrosing Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis.
    Piotrowski WJ; Martusewicz-Boros MM; Białas AJ; Barczyk A; Batko B; Błasińska K; Boros PW; Górska K; Grzanka P; Jassem E; Jastrzębski D; Kaczyńska J; Kowal-Bielecka O; Kucharz E; Kuś J; Kuźnar-Kamińska B; Kwiatkowska B; Langfort R; Lewandowska K; Mackiewicz B; Majewski S; Makowska J; Miłkowska-Dymanowska J; Puścińska E; Siemińska A; Sobiecka M; Soroka-Dąda RA; Szołkowska M; Wiatr E; Ziora D; Śliwiński P
    Adv Respir Med; 2022 Oct; 90(5):425-450. PubMed ID: 36285980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
    Gibson CD; Kugler MC; Deshwal H; Munger JS; Condos R
    Lung; 2020 Aug; 198(4):597-608. PubMed ID: 32591895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic and Therapeutic Developments in Progressive Pulmonary Fibrosis.
    Molina-Molina M; Buendia-Roldan I; Castillo D; Caro F; Valenzuela C; Selman M
    Arch Bronconeumol; 2022 May; 58(5):418-424. PubMed ID: 35312511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between acute exacerbation and progressive pulmonary fibrosis in interstitial lung disease: a retrospective cohort study.
    Zhai L; Wang Z; Yu W
    Ther Adv Respir Dis; 2024; 18():17534666241276800. PubMed ID: 39235441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review and meta-analysis of the clinical benefits and adverse reactions of anti-fibrotics in non-IPF progressive fibrosing ILD.
    Chong WH; Agrawal D; Tan ZY; Venkateswaran S; Tan AYY; Tan CY; Ling NCA; Tay NSWT
    Heart Lung; 2024; 68():242-253. PubMed ID: 39089077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapidly non-ipf progressive fibrosing interstitial lung disease: a phenotype with an ipf-like behavior.
    Khine N; Mudawi D; Rivera-Ortega P; Leonard C; Chaudhuri N; Margaritopoulos GA
    Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):231-233. PubMed ID: 33093788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pursuing Clinical Predictors and Biomarkers for Progression in ILD: Analysis of the Pulmonary Fibrosis Foundation (PFF) Registry.
    Chang SE; Jia G; Gao X; Schiffman C; Gupta S; Wolters P; Neighbors M
    Lung; 2024 Jun; 202(3):269-273. PubMed ID: 38753183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and Management of Fibrotic Interstitial Lung Diseases.
    Collins BF; Luppi F
    Clin Chest Med; 2021 Jun; 42(2):321-335. PubMed ID: 34024407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
    Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pirfenidone in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
    Ghazipura M; Mammen MJ; Bissell BD; Macrea M; Herman DD; Hon SM; Kheir F; Khor YH; Knight SL; Raghu G; Wilson KC; Hossain T
    Ann Am Thorac Soc; 2022 Jun; 19(6):1030-1039. PubMed ID: 35499847
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.